<p>都柏林 --（商业资讯）--Prothena Corporation plc（纳斯达克：PRTA）是一家处于后期临床阶段的生物技术公司，拥有基于蛋白质失调专业知识的强大研发管线，今天宣布 Paula Cobb 将辞去 Prothena 董事会职务，加入 Manifold Bio 担任首席运营官。在她六年的任期内，Cobb 女士在公司愿景和战略方面做出了重要贡献。</p>
<p>“我想感谢 Paula 在过去六年中的诸多贡献。作为一名拥有广泛全球开发、商业战略和商业专业知识的生物技术高管，她为董事会和领导层提供了宝贵的见解，” Prothena 董事会主席 Daniel G. Welch 表示。“整个董事会都非常感谢 Paula 自 2019 年加入董事会以来的战略专业知识和影响力，并祝愿她在新角色中继续取得成功。”</p>
<p>“在过去六年中，我很荣幸能在 Prothena 董事会任职，” Cobb 表示。“我为我们共同取得的成就感到自豪，并对公司开发变革性药物以治疗因蛋白质失调而遭受严重疾病的患者的战略愿景充满信心。”</p>
<p>随着 Cobb 女士的离职，Prothena 董事会现有 8 名董事。</p>
<p><strong>关于 Prothena</strong></p>
<p>Prothena Corporation plc 是一家处于后期临床阶段的生物技术公司，专注于蛋白质失调，拥有一系列具有潜力改变严重神经退行性疾病和罕见外周淀粉样病的研发药物。凭借数十年研究积累的深厚科学专业知识，Prothena 正在推进一系列治疗候选药物，针对多种适应症和新靶点，利用其在神经功能障碍和错误折叠蛋白生物学方面的科学见解。Prothena 的管线包括完全拥有和合作开发的项目，旨在潜在治疗包括伴有心肌病的 ATTR 淀粉样变、阿尔茨海默病、帕金森病以及其他多种神经退行性疾病。有关更多信息，请访问公司网站 www.prothena.com，并在 X（前身为 Twitter）上关注公司 @ProthenaCorp。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212675747/en/</p>
<p>Mark Johnson, CFA</p>
<p>投资者关系副总裁</p>
<p>650-837-8550</p>
<p>IR@prothena.com</p>
<p>Media@prothena.com</p>
<p>来源：Prothena Corporation plc</p>

PRTA

<p>Prothena Corporation 宣布 Paula Cobb 将辞去董事会职务，加入 Manifold Bio 担任首席运营官。Cobb 在 Prothena 任职六年期间对公司的愿景和战略做出了重要贡献。董事会对她的战略专长表示感谢，并祝愿她在新职位上取得成功。Prothena 目前董事会成员共有 8 位</p>

<p>DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena’s Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company’s vision and strategy.</p>
<div class="lb-trans"><p>都柏林 --（商业资讯）--Prothena Corporation plc（纳斯达克：PRTA）是一家处于后期临床阶段的生物技术公司，拥有基于蛋白质失调专业知识的强大研发管线，今天宣布 Paula Cobb 将辞去 Prothena 董事会职务，加入 Manifold Bio 担任首席运营官。在她六年的任期内，Cobb 女士在公司愿景和战略方面做出了重要贡献。</p>
</div><p>“I would like to thank Paula for her many contributions during the past six years. As a biotechnology executive with wide-ranging global development, business strategy and commercial expertise, she provided valuable insights to the board and leadership,” said Daniel G. Welch, Chair of Prothena’s Board of Directors. “The entire board of directors appreciates Paula’s strategic expertise and impact since joining the board in 2019 and we wish her continued success in her new role.”</p>
<div class="lb-trans"><p>“我想感谢 Paula 在过去六年中的诸多贡献。作为一名拥有广泛全球开发、商业战略和商业专业知识的生物技术高管，她为董事会和领导层提供了宝贵的见解，” Prothena 董事会主席 Daniel G. Welch 表示。“整个董事会都非常感谢 Paula 自 2019 年加入董事会以来的战略专业知识和影响力，并祝愿她在新角色中继续取得成功。”</p>
</div><p>“I have been honored to serve on the Prothena Board during these past six years,” said Cobb. “I am proud of what we accomplished together and remain confident in the company’s strategic vision to develop transformative medicines for patients suffering from devasting diseases caused by protein dysregulation.”</p>
<div class="lb-trans"><p>“在过去六年中，我很荣幸能在 Prothena 董事会任职，” Cobb 表示。“我为我们共同取得的成就感到自豪，并对公司开发变革性药物以治疗因蛋白质失调而遭受严重疾病的患者的战略愿景充满信心。”</p>
</div><p>With the departure of Ms. Cobb, Prothena has 8 Directors on its board.</p>
<div class="lb-trans"><p>随着 Cobb 女士的离职，Prothena 董事会现有 8 名董事。</p>
</div><p><strong>About Prothena</strong></p>
<div class="lb-trans"><p><strong>关于 Prothena</strong></p>
</div><p>Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.</p>
<div class="lb-trans"><p>Prothena Corporation plc 是一家处于后期临床阶段的生物技术公司，专注于蛋白质失调，拥有一系列具有潜力改变严重神经退行性疾病和罕见外周淀粉样病的研发药物。凭借数十年研究积累的深厚科学专业知识，Prothena 正在推进一系列治疗候选药物，针对多种适应症和新靶点，利用其在神经功能障碍和错误折叠蛋白生物学方面的科学见解。Prothena 的管线包括完全拥有和合作开发的项目，旨在潜在治疗包括伴有心肌病的 ATTR 淀粉样变、阿尔茨海默病、帕金森病以及其他多种神经退行性疾病。有关更多信息，请访问公司网站 www.prothena.com，并在 X（前身为 Twitter）上关注公司 @ProthenaCorp。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI2NzU3NDdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212675747r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212675747/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212675747/en/</p>
</div><p>Mark Johnson, CFA</p>
<div class="lb-trans"><p>Mark Johnson, CFA</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>投资者关系副总裁</p>
</div><p>650-837-8550</p>
<div class="lb-trans"><p>650-837-8550</p>
</div><p>IR@prothena.com</p>
<div class="lb-trans"><p>IR@prothena.com</p>
</div><p>Media@prothena.com</p>
<div class="lb-trans"><p>Media@prothena.com</p>
</div><p>Source: Prothena Corporation plc</p>
<div class="lb-trans"><p>来源：Prothena Corporation plc</p>
</div>

Prothena 宣布董事会更新 | PRTA 股票新闻